NasdaqGS - Delayed Quote USD

Illumina, Inc. (ILMN)

116.69 -1.60 (-1.35%)
At close: April 18 at 4:00 PM EDT
115.77 -0.92 (-0.79%)
After hours: April 18 at 7:27 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,504,000.00
4,504,000.00
4,584,000.00
4,526,000.00
3,239,000.00
Cost of Revenue
1,760,000.00
1,760,000.00
1,612,000.00
1,372,000.00
1,036,000.00
Gross Profit
2,744,000.00
2,744,000.00
2,972,000.00
3,154,000.00
2,203,000.00
Operating Expense
2,966,000.00
2,966,000.00
2,618,000.00
3,277,000.00
1,623,000.00
Operating Income
-222,000.00
-222,000.00
354,000.00
-123,000.00
580,000.00
Net Non Operating Interest Income Expense
-19,000.00
-19,000.00
-15,000.00
-61,000.00
-8,000.00
Other Income Expense
-876,000.00
-876,000.00
-4,675,000.00
1,068,000.00
284,000.00
Pretax Income
-1,117,000.00
-1,117,000.00
-4,336,000.00
884,000.00
856,000.00
Tax Provision
44,000.00
44,000.00
68,000.00
122,000.00
200,000.00
Net Income Common Stockholders
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Diluted NI Available to Com Stockholders
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Basic EPS
-7.10
-7.34
-28.00
5.07
4.48
Diluted EPS
-7.10
-7.34
-28.00
5.04
4.45
Basic Average Shares
157,750.00
158,000.00
157,000.00
150,000.00
147,000.00
Diluted Average Shares
157,750.00
158,000.00
157,000.00
151,000.00
148,000.00
Total Operating Income as Reported
-1,069,000.00
-1,069,000.00
-4,179,000.00
-123,000.00
580,000.00
Total Expenses
4,726,000.00
4,726,000.00
4,230,000.00
4,649,000.00
2,659,000.00
Net Income from Continuing & Discontinued Operation
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Normalized Income
-468,170.00
-468,170.00
-721,020.00
-150,858.00
656,000.00
Interest Income
58,000.00
58,000.00
11,000.00
--
41,000.00
Interest Expense
77,000.00
77,000.00
26,000.00
61,000.00
49,000.00
Net Interest Income
-19,000.00
-19,000.00
-15,000.00
-61,000.00
-8,000.00
EBIT
-1,040,000.00
-1,040,000.00
-4,310,000.00
945,000.00
905,000.00
EBITDA
-608,000.00
-608,000.00
-3,916,000.00
1,196,000.00
1,092,000.00
Reconciled Cost of Revenue
1,760,000.00
1,760,000.00
1,612,000.00
1,372,000.00
1,036,000.00
Reconciled Depreciation
432,000.00
432,000.00
394,000.00
251,000.00
187,000.00
Net Income from Continuing Operation Net Minority Interest
-1,161,000.00
-1,161,000.00
-4,404,000.00
762,000.00
656,000.00
Total Unusual Items Excluding Goodwill
-877,000.00
-877,000.00
-4,662,000.00
1,059,000.00
--
Total Unusual Items
-877,000.00
-877,000.00
-4,662,000.00
1,059,000.00
--
Normalized EBITDA
269,000.00
269,000.00
746,000.00
137,000.00
1,092,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-184,170.00
-184,170.00
-979,020.00
146,142.00
--
12/31/2020 - 7/28/2000
Yahoo Finance Plus Essential access required. Unlock Access

Related Tickers

EXAS Exact Sciences Corporation
63.48
+0.41%
 
GH Guardant Health, Inc.
16.67
+1.71%
 
TMO Thermo Fisher Scientific Inc.
541.52
-1.05%
 
TWST Twist Bioscience Corporation
28.36
-0.74%
 
A Agilent Technologies, Inc.
132.44
-1.57%
 
IDXX IDEXX Laboratories, Inc.
477.79
-0.09%
 
DHR Danaher Corporation
236.36
-1.27%
 
MTD Mettler-Toledo International Inc.
1,192.56
-0.46%
 
CRL Charles River Laboratories International, Inc.
227.55
-1.10%
 
IQV IQVIA Holdings Inc.
227.17
-0.04%